<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04536558</url>
  </required_header>
  <id_info>
    <org_study_id>HS-TN-001</org_study_id>
    <nct_id>NCT04536558</nct_id>
  </id_info>
  <brief_title>Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study</brief_title>
  <acronym>OFFER</acronym>
  <official_title>Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study（OFFER）</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu Hansoh Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, controlled, double-blind, phase III study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, controlled, double-blind, phase III study assessing the&#xD;
      efficacy and safety of Olanzapine plus fosaprepitant plus ondansetron and dexamethasone&#xD;
      versus fosaprepitant plus ondansetron and dexamethasone in the prevention of&#xD;
      chemotherapy-induced nausea and vomiting in patients receiving high emetic risk multi-day&#xD;
      chemotherapy. Eligible patients will be randomized to receive either olanzapine plus&#xD;
      fosaprepitant standard antiemetic therapy or fosaprepitant standard antiemetic therapy in a&#xD;
      1:1 ratio.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response (CR) during overall phase</measure>
    <time_frame>Day 1 to day 8 after highly emetogenic chemotherapy initiation</time_frame>
    <description>To compare olanzapine plus fosaprepitant regimen with placebo plus fosaprepitant regimen with respect to efficacy; complete response (CR) defined as no vomiting and no use of rescue therapy during overall phase (day 1 to day 8） after highly emetogenic chemotherapy initiation)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR) during acute phase</measure>
    <time_frame>Day 1 to day 3 days after highly emetogenic chemotherapy initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR) during delayed phase</measure>
    <time_frame>Day 4 to day 8 after highly emetogenic chemotherapy initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No significant nausea during overall phase using questionnaire</measure>
    <time_frame>Day 1 to day 8 after highly emetogenic chemotherapy initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No significant nausea during acute phase using questionnaire</measure>
    <time_frame>Day 1 to day 3 after highly emetogenic chemotherapy initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No significant nausea during delayed phase using questionnaire</measure>
    <time_frame>Day 4 to day 8 after highly emetogenic chemotherapy initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare quality of life using the functional living index-emesis questionnaire</measure>
    <time_frame>From baseline to day 8 after highly emetogenic chemotherapy initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare olanzapine plus fosaprepitant regimen with placebo plus fosaprepitant regimen in terms of the number of days to first emetic episode.</measure>
    <time_frame>Day 1 to day 8 after highly emetogenic chemotherapy initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>From baseline to day 8 after highly emetogenic chemotherapy initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the change of score using Hospital Anxiety and Depression Scale</measure>
    <time_frame>From baseline to day 8 after highly emetogenic chemotherapy initiation</time_frame>
    <description>Hospital Anxiety and Depression Scale includes two subscales: anxiety and depression, with 7 items for anxiety (a) and depression (d) respectively. Each item is divided into four grades of 0-3. The higher the score is, the more serious the anxiety and depression are.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The plasma concentration of 5-hydroxytryptamine and substance P at the baseline</measure>
    <time_frame>From baseline to day 8 after highly emetogenic chemotherapy initiation</time_frame>
    <description>To explore the relationship between plasma concentration of 5-hydroxytryptamine、substance P and efficacy</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">352</enrollment>
  <condition>Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy</condition>
  <arm_group>
    <arm_group_label>olanzapine plus fosaprepitant-based triple regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olanzapine（5mg p.o. d1-d5）plus fosaprepitant（150mg i.v. d1-d3） plus ondansetron（8mg i.v. d1-d3）and dexamethasone（6mg p.o. d1-d5） before undergoing chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus fosaprepitant-based triple regimen</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo plus fosaprepitant（150mg i.v. d1-d3） plus ondansetron（8mg i.v. d1-d3）and dexamethasone（6mg p.o. d1-d5） before undergoing chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olanzapine plus fosaprepitant-based triple regimen</intervention_name>
    <description>olanzapine 5mg p.o. on day 1-day 5, fosaprepitant 150mg i.v. on day 1 before undergoing chemotherapy. Patients received ondansetron hydrochloride(8mg, i.v. day 1-day 3) and dexamethasone(6mg, oral, day 1-day 5) at the same time, before undergoing chemotherapy.</description>
    <arm_group_label>olanzapine plus fosaprepitant-based triple regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo plus fosaprepitant-based triple regimen</intervention_name>
    <description>placebo p.o. on day 1-day 5, fosaprepitant 150mg i.v. on day 1 before undergoing chemotherapy. Patients received ondansetron hydrochloride(8mg, i.v. day 1-day 3) and dexamethasone(6mg, oral, day 1-day 5) at the same time, before undergoing chemotherapy.</description>
    <arm_group_label>Placebo plus fosaprepitant-based triple regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: (abbreviated)&#xD;
&#xD;
          1. Male and female patients aged ≥ 18 and ≤ 75 years old;&#xD;
&#xD;
          2. Patients were diagnosed with histologically or cytology confirmed solid malignant&#xD;
             tumors;&#xD;
&#xD;
          3. Patients have a Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2;&#xD;
&#xD;
          4. Patients were predicted life expectancy of ≥ 3 months;&#xD;
&#xD;
          5. Patients who were scheduled for 3 days of cisplatin based chemotherapy.&#xD;
&#xD;
        Exclusion Criteria: (abbreviated)&#xD;
&#xD;
          1. Patients were mentally disable or suffered from emotional disorders;&#xD;
&#xD;
          2. Patients were current illicit drug use, including alcohol abuse;&#xD;
&#xD;
          3. Patients scheduled administration of stem cell rescue therapy during cisplatin&#xD;
             chemotherapy;&#xD;
&#xD;
          4. Patients have participated in other clinical trials in the past 4 weeks;&#xD;
&#xD;
          5. Patients were treated with chemotherapy including ordinary paclitaxel(using castor oil&#xD;
             as a solvent);&#xD;
&#xD;
          6. Patients with active infections (e.g., pneumonia) or any uncontrolled disease (e.g.,&#xD;
             diabetic ketoacidosis, gastrointestinal obstruction) other than malignant tumors, and&#xD;
             the researchers believe that it may confound the results of the study or expose&#xD;
             patients receiving treatment with the study drug at unnecessary risk;&#xD;
&#xD;
          7. Patients have any disease that the researcher believes may confound the results of the&#xD;
             study or expose the patient to unnecessary risk；&#xD;
&#xD;
          8. Patients were treated with moderate or highly emetogenic chemotherapy within 6 days&#xD;
             prior to the initial of cisplatin infusion and/or 6 days after cisplatin infusion;&#xD;
&#xD;
          9. Patients were scheduled to receive radiation therapy to the abdomen or pelvis within a&#xD;
             week of treatment;&#xD;
&#xD;
         10. Absolute neutrophil count&lt;1,500 cells/ L, white blood cell count&lt;3,000 cells/ L,&#xD;
             platelet count&lt;100,000 cells/ L, aspartate aminotransferase and alanine&#xD;
             aminotransferase&gt;2.5 upper limit of normal (ULN), bilirubin &gt; 1.5 ULN, and creatinine&#xD;
             &gt; 1.5 ULN;&#xD;
&#xD;
         11. Patients were pregnant or breastfeeding;&#xD;
&#xD;
         12. Patients had suffered from vomiting or nausea in the 24 hours before treatment;&#xD;
&#xD;
         13. Patients were known to be at risk for narrow angle glaucoma；&#xD;
&#xD;
         14. Patients who are taking or have used CYP3A4 inducers within 30 days before the first&#xD;
             day of treatment, which will affect the efficacy of the treatment drugs according to&#xD;
             the researcher's evaluation, can not be enrolled;&#xD;
&#xD;
         15. Patients who are taking or have used CYP3A4 substrates and inhibitors within 7 days&#xD;
             before the first day of treatment will significantly increase the treatment&#xD;
             drug-related adverse events according to the researcher's evaluation, can not be&#xD;
             enrolled;&#xD;
&#xD;
         16. Within 48 hours before the first day of treatment, patients used the following&#xD;
             antiemetic agents: 5-hydroxytryptamine 3 receptor antagonists (such as ondansetron),&#xD;
             phenothiazines (such as prochlorperazine), benzophenones (such as haloperidol),&#xD;
             benzamide (such as metoclopramide), domperidone, cannabinoids, herbs with potential&#xD;
             antiemetic effects, scopolamine, and cyclizine, etc;&#xD;
&#xD;
         17. Patients began to receive benzodiazepines or opioids within 48 hours prior to the&#xD;
             first day of the study (except for triazolam, temazepam or midazolam single dose&#xD;
             daily);&#xD;
&#xD;
         18. Patients had symptomatic primary or metastatic central nervous system malignancies;&#xD;
&#xD;
         19. Patients had concomitant diseases that could not take dexamethasone for 5 days, such&#xD;
             as systemic fungal infection or uncontrolled diabetes mellitus;&#xD;
&#xD;
         20. Patients were not allowed to receive any dose of systemic glucocorticoid therapy&#xD;
             within 72 hours before the first day except those prescribed in the protocol; however,&#xD;
             local and inhaled corticosteroids were allowed;&#xD;
&#xD;
         21. Patients had a history of hypersensitivity to fosaprepitant meglumine, olanzapine,&#xD;
             ondansetron or dexamethasone；&#xD;
&#xD;
         22. Patients had been treated with neurokinin-1 receptor antagonist in the past;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Li Zhang</last_name>
    <phone>+86 20-87342288</phone>
    <email>zhangli@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jian Fang</last_name>
    </contact>
    <investigator>
      <last_name>Jian Fang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianchun Duan</last_name>
    </contact>
    <investigator>
      <last_name>Jianchun Duan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lin Wu</last_name>
    </contact>
    <investigator>
      <last_name>Lin Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sichuan Cancer Hospital&amp; Institute</name>
      <address>
        <city>Chengdou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wenxiu Yao</last_name>
    </contact>
    <investigator>
      <last_name>Wenxiu Yao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaopin Chen</last_name>
    </contact>
    <investigator>
      <last_name>Xiaopin Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangdong</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Li Zhang</last_name>
    </contact>
    <investigator>
      <last_name>Li Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Haerbin</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Li Cai</last_name>
    </contact>
    <investigator>
      <last_name>Li Cai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anhui Provincial Cancer Hospital</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Changlu Hu</last_name>
    </contact>
    <investigator>
      <last_name>Changlu Hu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yunnan Cancer Hospital</name>
      <address>
        <city>Kunming</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Runxiang Yang</last_name>
    </contact>
    <investigator>
      <last_name>Runxiang Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangxi Cancer Hospital</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yinglan Chen</last_name>
    </contact>
    <investigator>
      <last_name>Yinglan Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangxi Medical University Affiliated Tumor Hospital</name>
      <address>
        <city>Nanning</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qitao Yu</last_name>
    </contact>
    <investigator>
      <last_name>Qitao Yu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ningbo Medical Center Lihuili Hospital</name>
      <address>
        <city>Ningbo</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Sixth People's Hospital Affiliated to Shanghai JiaoTong University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Daliu Min</last_name>
    </contact>
    <investigator>
      <last_name>Daliu Min</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liaoning Cancer Hospital &amp; Institute</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Tao Sun</last_name>
    </contact>
    <investigator>
      <last_name>Tao Sun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Junfeng Liu</last_name>
    </contact>
    <investigator>
      <last_name>Junfeng Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Kai Chen</last_name>
    </contact>
    <investigator>
      <last_name>Kai Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Diansheng Zhong</last_name>
    </contact>
    <investigator>
      <last_name>Diansheng Zhong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yanqiu Zhao</last_name>
    </contact>
    <investigator>
      <last_name>Yanqiu Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>August 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2020</study_first_posted>
  <last_update_submitted>August 28, 2020</last_update_submitted>
  <last_update_submitted_qc>August 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Li Zhang, MD</investigator_full_name>
    <investigator_title>head of the medical department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

